d in this press release to reflect future results, events or developments.
Quill(TM) is a trademark of Quill Medical, Inc. and MONODERM(TM) is a trademark of Surgical Specialties Corporation, both of which are wholly-owned subsidiaries of Angiotech Pharmaceuticals, Inc.
(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.
'/>"/>SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 20092.
Angiotech announces date of annual general meeting of shareholders3.
Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast4.
Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.5.
Angiotech announces positive results from Bio-Seal(TM) clinical study6.
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 20087.
Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities8.
Angiotech Pharmaceuticals announces time change of conference call and webcast9.
Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners10.
Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders11.
Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014